Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune

Sara Zahraeifard1, Zhiguang Xiao1, Jae Young So1

  • 1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Nature Communications
|July 12, 2024
PubMed

Insights

Loss of tumor suppressors (TS) creates an immune-suppressive tumor microenvironment, hindering cancer immunotherapy. Targeting immune checkpoints like LAG3 offers a new strategy for treating cancers with inactivated TS.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Immune checkpoint blockade (ICB) faces challenges with low response rates, relapse, and resistance in cancer treatment.
  • Loss of tumor suppressors (TS) can promote an immune-suppressive tumor microenvironment and is linked to increased immune checkpoint inhibitor expression.

Purpose of the Study:

  • To identify tumor suppressors that regulate the immune microenvironment and immune checkpoint mediator expression.
  • To investigate the therapeutic potential of targeting specific immune checkpoints in tumors with inactivated tumor suppressors.

Main Methods:

  • Utilized in vivo CRISPR/Cas9 loss-of-function screening to identify key tumor suppressors.
  • Analyzed chromatin accessibility and inflammatory pathways (IL6-JAK3-STAT3/6) upon TS loss.
  • Assessed the efficacy of combined LAG3 and PD-L1 blockade in preclinical triple-negative breast cancer (TNBC) models.

Main Results:

  • Identified NF1, TSC1, and TGF-β RII as tumor suppressors regulating immune composition.
  • Loss of these TSs alters chromatin accessibility, enhances inflammatory pathways, and promotes an immune-suppressive landscape with increased LAG3+ T cells.
  • Simultaneous blockade of LAG3 and PD-L1 inhibited metastasis in preclinical models of NF1-, TSC1-, or TGF-β RII-deficient TNBC.

Conclusions:

  • Tumor suppressors play a critical role in modulating the immune compartment and metastasis through non-cell-autonomous mechanisms.
  • Targeting LAG3, in combination with PD-L1, presents a promising therapeutic strategy for patients with cancers harboring inactivated NF1, TSC1, or TGF-β RII.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
996
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K